A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells

Acute myeloid leukemia (AML) represents an aggressive hematopoietic malignancy with a prognosis inferior to that of other leukemias. Recent targeted therapies offer new opportunities to achieve better treatment outcomes. However, due to the complex heterogeneity of AML, its prognosis remains dismal....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kunlong, Gao, Li, Wang, Jianwei, Chu, Xinran, Zhang, Zimu, Zhang, Yongping, Fang, Fang, Tao, Yanfang, Li, Xiaolu, Tian, Yuanyuan, Li, Zhiheng, Sang, Xu, Ma, Li, Lu, Lihui, Chen, Yanling, Yu, Juanjuan, Zhuo, Ran, Wu, Shuiyan, Pan, Jian, Hu, Shaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272305/
https://www.ncbi.nlm.nih.gov/pubmed/35832114
http://dx.doi.org/10.3389/pore.2022.1610447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272305/
https://www.ncbi.nlm.nih.gov/pubmed/35832114
http://dx.doi.org/10.3389/pore.2022.1610447

Ejemplares similares